<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036005</url>
  </required_header>
  <id_info>
    <org_study_id>IFG-08-2019</org_study_id>
    <nct_id>NCT05036005</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)</brief_title>
  <acronym>NeoON</acronym>
  <official_title>Neoadjuvant Treatment of Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label, Multicenter, Phase IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer Frauengesundheit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer Frauengesundheit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of patients with HER2 positive early breast cancer has continuously improved&#xD;
      over the last decades. Up to now both, trastuzumab and pertuzumab are approved in combination&#xD;
      with chemotherapy (CTX) not only for the adjuvant but also for the neoadjuvant treatment of&#xD;
      early breast cancer patients. A high pCR rate in the neoadjuvant setting was shown in several&#xD;
      trials and observational studies with CTX+ trastuzumab and with CTX+ pertuzumab. The efficacy&#xD;
      is dependent on a variety of mechanisms including the blocking of the important PI3K/Akt and&#xD;
      MAPK pathways, and ADCC (antibody dependent cellular toxicity).&#xD;
&#xD;
      Recently the biosimilar Ontruzant® (SB3) has been introduced into the treatment of HER2&#xD;
      positive breast cancer as a biosimilar. Efficacy and toxicity have been shown to be&#xD;
      equivalent to the first approved antibody, however, data from the real-world setting have not&#xD;
      been published like it has for the originally approved antibody. Therefore, the aim of this&#xD;
      study is to establish safety and efficacy for Ontruzant® in the real world setting. Patients&#xD;
      can be included if they are treated with Ontruzant® in the neoadjuvant setting. Additionally,&#xD;
      the study will be accompanied by a comprehensive immune monitoring program and biomarker&#xD;
      program to explore immune oncology potential for the neoadjuvant treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>Pathological complete response will be assessed at final surgery.</time_frame>
    <description>Pathological complete response (pCR) rate, defined as the complete absence of tumor cells (ypT0; ypN0) after neoadjuvant study treatment of HER2-positive early breast cancer patients treated with Ontruzant® (SB3) in combination with pertuzumab (optional) and a standard chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR) rate in patients without pertuzumab</measure>
    <time_frame>Pathological complete response will be assessed at final surgery.</time_frame>
    <description>Pathological complete response (pCR) rate, defined as the complete absence of tumor cells (ypT0; ypN0) after neoadjuvant study treatment of HER2-positive early breast cancer patients treated with Ontruzant® (SB3) and a standard chemotherapy who were not treated with pertuzumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants wuth treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Adverse ebents will be assessed from first administration of trial treatment until 30 days after last administration of trial treatment.</time_frame>
    <description>The safety endpoints for the study will include rate of AE/SAEs and fatal SAEs, causality and outcome of AE/SAEs, rate of treatment discontinuations and reasons, Changes in vital signs, laboratory values etc. Grading of AE/SAEs will be based on NCI CTCAE v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-C30</measure>
    <time_frame>Every nine weeks from first administration of trial medication through study completion, up to 30 days after administration of last medication.</time_frame>
    <description>To evaluate changes in health related quality of life (QoL) assessments from baseline in all subjects using Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-BR23</measure>
    <time_frame>Every nine weeks from first administration of trial medication through study completion, up to 30 days after administration of last medication.</time_frame>
    <description>To evaluate changes in health related quality of life (QoL) assessments from baseline in all subjects using Quality of Life Questionnaire Breast Cancer-Specific Quality of Life (EORTC QLQ-BR23).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the antibody-dependent cell mediated cytotoxicity (ADCC)</measure>
    <time_frame>Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery</time_frame>
    <description>ADCC will be quantified and immune phenotyping will be performed from peripheral blood mononuclear cells (PBMCs).</description>
  </other_outcome>
  <other_outcome>
    <measure>FcγR genotypes</measure>
    <time_frame>Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery</time_frame>
    <description>Germline DNA will be genotyped in order to specify FcγR polymorphisms and impact of FcγR genotypes on ADCC and pCR will be assessed.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer Female</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ontruzant + Pertuzumab (optional) + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive 6 cycles of Ontruzant® i.v. q21d in combination with standard chemotherapy with or without pertuzumab, at the discretion of investigator's decision. Initial dose of Ontruzant® i.v. will be 8 mg/kg b.w. followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d. Clinical and bioptic tumor assessment will be performed during baseline and during surgery.&#xD;
Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned for 30 days after the last administration of study medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ontruzant</intervention_name>
    <description>All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.</description>
    <arm_group_label>Ontruzant + Pertuzumab (optional) + Chemotherapy</arm_group_label>
    <other_name>SB3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator</description>
    <arm_group_label>Ontruzant + Pertuzumab (optional) + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.</description>
    <arm_group_label>Ontruzant + Pertuzumab (optional) + Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent prior to beginning of trial specific procedures.&#xD;
&#xD;
          2. Subject must be female and aged ≥ 18 years on day of signing informed consent.&#xD;
&#xD;
          3. ECOG 0-1.&#xD;
&#xD;
          4. Histologically confirmed, early HER2 positive breast cancer determined by core biopsy&#xD;
             of breast tumor lesion.&#xD;
&#xD;
          5. Measurable tumor lesion with a size of ≥ 1 cm assessed by sonography or magnetic&#xD;
             resonance imaging (MRI) within ≤ 28 days prior to entry. In case of inflammatory&#xD;
             disease, the extent of inflammation will be measured.&#xD;
&#xD;
          6. Indication for chemotherapy.&#xD;
&#xD;
          7. Multicentric and/or multifocal disease as well as synchronous bilateral breast cancer&#xD;
             is eligible as long as one measurable lesion meets all inclusion criteria. The&#xD;
             investigator has to determine which lesion will be used for tumor evaluation before&#xD;
             initiation of treatment.&#xD;
&#xD;
          8. Complete staging within 8 weeks prior to entry with no evidence of distant disease,&#xD;
             including bilateral mammography, breast ultrasound, chest-X-ray (or chest CT-scan),&#xD;
             liver ultrasound (or liver CT-scan or liver MRI) and bone scan.&#xD;
&#xD;
          9. Subjects must provide a core biopsy from tumor lesion before first chemotherapy, after&#xD;
             3 cycles of chemotherapy and after last neoadjuvant study treatment for biomarker&#xD;
             analyses.&#xD;
&#xD;
         10. Adequate organ function defined as: Absolute neutrophile count ≥1500/µL, Platelets&#xD;
             ≥100 000/µL, Hemoglobin ≥10.0 g/dL or ≥6.2 mmol/L, Creatinine ≤1.5 × ULN OR measured&#xD;
             or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels&#xD;
             &gt;1.5 × institutional ULN (GFR can also be used in place of creatinine or CrCl), Total&#xD;
             bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin&#xD;
             levels &gt;1.5 × ULN, AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants&#xD;
             with liver metastases), International normalized ratio (INR) OR prothrombin time (PT)&#xD;
             ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT&#xD;
             is within therapeutic range of intended use of anticoagulants, LVEF &gt; 50 %&#xD;
&#xD;
         11. Female subjects of childbearing potential must have a negative urine pregnancy test&#xD;
             within 72 h prior to study entry and be willing to use an adequate method of&#xD;
             contraception for course of the study through 7 months after the last dose of trial&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent participation in a study with an investigational agent/device or within 14&#xD;
             days of study entry.&#xD;
&#xD;
          2. Prior chemotherapy, radiation therapy or small molecule therapy for any reason.&#xD;
&#xD;
          3. Previous malignant disease being disease-free for less than 3 years (except in situ&#xD;
             carcinoma of the cervix and basal cell carcinoma of the skin).&#xD;
&#xD;
          4. Pregnancy or lactation.&#xD;
&#xD;
          5. Prior neoadjuvant therapy.&#xD;
&#xD;
          6. Active infection requiring systemic therapy.&#xD;
&#xD;
          7. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.&#xD;
&#xD;
          8. Active autoimmune disease or other diseases that requires systemic treatment with&#xD;
             corticosteroids or immunosuppressive drugs (physiologic corticosteroid replacement&#xD;
             therapy for adrenal or pituitary insufficiency is allowed).&#xD;
&#xD;
          9. History of primary or acquired immunodeficiency (including allogenic organ&#xD;
             transplant).&#xD;
&#xD;
         10. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,&#xD;
             ulcerative colitis).&#xD;
&#xD;
         11. Known history of following infections: Human immunodeficiency virus (HIV), History of&#xD;
             acute or chronic Hepatitis B or Hepatitis C, has received a live-virus vaccination&#xD;
             within 30 days of planned treatment start. Seasonal flu vaccines that do not contain&#xD;
             live virus are permitted.&#xD;
&#xD;
         12. Known congestive heart failure &gt; NYHA I and/or coronary heart disease, angina&#xD;
             pectoris, previous history of myocardial infarction, uncontrolled or poorly controlled&#xD;
             arterial hypertension (e.g. blood pressure &gt;160/90 mmHg under treatment with two or&#xD;
             more antihypertensive drugs), rhythm disorders with clinically significant valvular&#xD;
             heart disease.&#xD;
&#xD;
         13. Pre-existing motor or sensory neuropathy of a severity grade ≥2 by National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0.&#xD;
&#xD;
         14. Any other condition in opinion of the investigator that would interfere with applied&#xD;
             systemic treatment or other trial procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Lüftner, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Department for Hematology, Oncology and Tumor Immunology Charité Campus Benjamin Franklin, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Schneeweiss, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>National Center for Tumor Diseases (NCT), Head of Division Head of Division Gynecologic Oncology, Heidelberg University Hospital (UKHD)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NeoON Study Manager</last_name>
    <phone>+49 9131 9279136</phone>
    <email>neo.on@ifg-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division Gynecologic Oncology, Heidelberg University Hospital (UKHD)</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Schneeweiss, MD, Prof.</last_name>
      <phone>+49 (0) 6221 563 6051</phone>
      <email>andreas.schneeweiss@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology, Tübingen University Hospital</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Hartkopf, MD, Prof.</last_name>
      <phone>+49 70712982211</phone>
      <email>andreas.hartkopf@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bavaria</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manfred Welslau, MD</last_name>
      <phone>+49 6021 4527300</phone>
      <email>info@onkologie-ab.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, Erlangen University Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter A Fasching, MD, Prof.</last_name>
      <phone>+49 9131 8543470</phone>
      <email>peter.fasching@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology, University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>Haburg</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volkmar Müller, MD, Prof.</last_name>
      <phone>+49 40 7410 - 52510</phone>
      <email>vmueller@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Hematology and Oncology Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Tesch, MD, Prof.</last_name>
      <phone>+49 69 451080</phone>
      <email>info@onkologie-bethanien.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, University Medicine Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Hesse</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Schmidt, MD, Prof.</last_name>
      <phone>+49 6131 176884</phone>
      <email>marcus.schmidt@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH</name>
      <address>
        <city>Bottrop</city>
        <state>North Rhine-Westphalia</state>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Christian Kolberg, MD</last_name>
      <phone>+49 2041 1061601</phone>
      <email>hans-christian.kolberg@mhb-bottrop.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, Dresden University Hospital Carl-Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Wimberger, MD, Prof.</last_name>
      <phone>+49 351 4583420</phone>
      <email>pauline.wimberger@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department for Hematology, Oncology and Tumor Immunology Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>122000</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Lüftner, MD, Prof.</last_name>
      <phone>+49 30 450513524</phone>
      <email>diana.lueftner@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Untch, MD, Prof.</last_name>
      <phone>+49 30 940153300</phone>
      <email>michael.untch@helios-gesundheit.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ontruzant</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Pertuzumab</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

